Trends in antiseizure medication prescription patterns among all adults, women, and older adults with epilepsy : A German longitudinal analysis from 2008 to 2020
Copyright © 2022 Elsevier Inc. All rights reserved..
INTRODUCTION: The prescription patterns of antiseizure medication (ASM) are subject to new scientific evidence and sociodemographic and practical aspects. This study analyzed trends in ASM prescription patterns among all adults with epilepsy, with special consideration for women of childbearing potential (WOCBP) and older adult (≥65 years old) patients.
METHODS: Data from four questionnaire-based cohort studies, conducted in 2008, 2013, 2016, and 2020, were analyzed for ASM prescription frequencies and common mono- and dual therapy regimens. Statistical comparisons were performed with the Chi-square test and one-way analysis of variance.
RESULTS: Overall, the individual prescription patterns among 1,642 adult patients with epilepsy were analyzed. A significant increase in the prescription frequency of third-generation ASMs, from 59.3% to 84.2% (p = 0.004), was accompanied by a decrease in the frequency of first- and second-generation ASMs (5.4% to 2.1% and 34.9% to 12.6%, respectively). This trend was accompanied by a significant decrease in the use of enzyme-inducing ASMs, from 23.9% to 4.6% (p = 0.004). Among frequently prescribed ASMs, prescriptions of carbamazepine (18.6% to 3.1%, p = 0.004) and valproate (15.4% to 8.7%, p = 0.004) decreased, whereas prescriptions of levetiracetam (18.0% up to 32.4%, p = 0.004) increased significantly. The prescription frequency of lamotrigine remained largely constant at approximately 20% (p = 0.859). Among WOCBP, the prescription frequencies of carbamazepine (11.4% to 2.0%, p = 0.004) and valproate (16.1% to 6.1%, p = 0.004) decreased significantly. Levetiracetam monotherapy prescriptions increased significantly (6.6% to 30.4%, p = 0.004) for WOCBP, whereas lamotrigine prescriptions remained consistent (37.7% to 44.9%, p = 0.911). Among older adult patients, a significant decrease in carbamazepine prescriptions (30.1% to 7.8%, p = 0.025) was the only relevant change in ASM regimens between 2008 and 2020. In patients with genetic generalized epilepsies, levetiracetam was frequently used as an off-label monotherapy (25.0% to 35.3%).
CONCLUSION: These results show a clear trend toward the use of newer and less interacting third-generation ASMs, with lamotrigine, levetiracetam, and lacosamide representing the current ASMs of choice, displacing valproate and carbamazepine over the last decade. In WOCBP, prescription patterns shifted to minimize teratogenic effects, whereas, among older adults, the decrease in carbamazepine use may reflect the avoidance of hyponatremia risks and attempts to reduce the interaction potential with other drugs and ASMs. Levetiracetam is frequently used off-label as a monotherapy in patients with genetic generalized epilepsy.
| Errataetall: |
CommentIn: Epilepsy Behav. 2022 May;130:108690. - PMID 35427939 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
|---|---|
| Enthalten in: |
Epilepsy & behavior : E&B - 130(2022) vom: 30. Mai, Seite 108666 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hochbaum, Maja [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.05.2022 Date Revised 01.07.2022 published: Print-Electronic CommentIn: Epilepsy Behav. 2022 May;130:108690. - PMID 35427939 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.yebeh.2022.108666 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338695850 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338695850 | ||
| 003 | DE-627 | ||
| 005 | 20231226001239.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.yebeh.2022.108666 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1128.xml |
| 035 | |a (DE-627)NLM338695850 | ||
| 035 | |a (NLM)35339390 | ||
| 035 | |a (PII)S1525-5050(22)00115-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hochbaum, Maja |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Trends in antiseizure medication prescription patterns among all adults, women, and older adults with epilepsy |b A German longitudinal analysis from 2008 to 2020 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.05.2022 | ||
| 500 | |a Date Revised 01.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Epilepsy Behav. 2022 May;130:108690. - PMID 35427939 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a INTRODUCTION: The prescription patterns of antiseizure medication (ASM) are subject to new scientific evidence and sociodemographic and practical aspects. This study analyzed trends in ASM prescription patterns among all adults with epilepsy, with special consideration for women of childbearing potential (WOCBP) and older adult (≥65 years old) patients | ||
| 520 | |a METHODS: Data from four questionnaire-based cohort studies, conducted in 2008, 2013, 2016, and 2020, were analyzed for ASM prescription frequencies and common mono- and dual therapy regimens. Statistical comparisons were performed with the Chi-square test and one-way analysis of variance | ||
| 520 | |a RESULTS: Overall, the individual prescription patterns among 1,642 adult patients with epilepsy were analyzed. A significant increase in the prescription frequency of third-generation ASMs, from 59.3% to 84.2% (p = 0.004), was accompanied by a decrease in the frequency of first- and second-generation ASMs (5.4% to 2.1% and 34.9% to 12.6%, respectively). This trend was accompanied by a significant decrease in the use of enzyme-inducing ASMs, from 23.9% to 4.6% (p = 0.004). Among frequently prescribed ASMs, prescriptions of carbamazepine (18.6% to 3.1%, p = 0.004) and valproate (15.4% to 8.7%, p = 0.004) decreased, whereas prescriptions of levetiracetam (18.0% up to 32.4%, p = 0.004) increased significantly. The prescription frequency of lamotrigine remained largely constant at approximately 20% (p = 0.859). Among WOCBP, the prescription frequencies of carbamazepine (11.4% to 2.0%, p = 0.004) and valproate (16.1% to 6.1%, p = 0.004) decreased significantly. Levetiracetam monotherapy prescriptions increased significantly (6.6% to 30.4%, p = 0.004) for WOCBP, whereas lamotrigine prescriptions remained consistent (37.7% to 44.9%, p = 0.911). Among older adult patients, a significant decrease in carbamazepine prescriptions (30.1% to 7.8%, p = 0.025) was the only relevant change in ASM regimens between 2008 and 2020. In patients with genetic generalized epilepsies, levetiracetam was frequently used as an off-label monotherapy (25.0% to 35.3%) | ||
| 520 | |a CONCLUSION: These results show a clear trend toward the use of newer and less interacting third-generation ASMs, with lamotrigine, levetiracetam, and lacosamide representing the current ASMs of choice, displacing valproate and carbamazepine over the last decade. In WOCBP, prescription patterns shifted to minimize teratogenic effects, whereas, among older adults, the decrease in carbamazepine use may reflect the avoidance of hyponatremia risks and attempts to reduce the interaction potential with other drugs and ASMs. Levetiracetam is frequently used off-label as a monotherapy in patients with genetic generalized epilepsy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anticonvulsants | |
| 650 | 4 | |a Antiepileptic drugs | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Older adult | |
| 650 | 4 | |a Polypharmacy | |
| 650 | 4 | |a Pregnancy | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Benzodiazepines |2 NLM | |
| 650 | 7 | |a 12794-10-4 |2 NLM | |
| 650 | 7 | |a Carbamazepine |2 NLM | |
| 650 | 7 | |a 33CM23913M |2 NLM | |
| 650 | 7 | |a Levetiracetam |2 NLM | |
| 650 | 7 | |a 44YRR34555 |2 NLM | |
| 650 | 7 | |a Valproic Acid |2 NLM | |
| 650 | 7 | |a 614OI1Z5WI |2 NLM | |
| 650 | 7 | |a Lamotrigine |2 NLM | |
| 650 | 7 | |a U3H27498KS |2 NLM | |
| 700 | 1 | |a Kienitz, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenow, Felix |e verfasserin |4 aut | |
| 700 | 1 | |a Schulz, Juliane |e verfasserin |4 aut | |
| 700 | 1 | |a Habermehl, Lena |e verfasserin |4 aut | |
| 700 | 1 | |a Langenbruch, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Kovac, Stjepana |e verfasserin |4 aut | |
| 700 | 1 | |a Knake, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a von Podewils, Felix |e verfasserin |4 aut | |
| 700 | 1 | |a von Brauchitsch, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Hamacher, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Strzelczyk, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Willems, Laurent M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Epilepsy & behavior : E&B |d 2000 |g 130(2022) vom: 30. Mai, Seite 108666 |w (DE-627)NLM123848776 |x 1525-5069 |7 nnns |
| 773 | 1 | 8 | |g volume:130 |g year:2022 |g day:30 |g month:05 |g pages:108666 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.yebeh.2022.108666 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 130 |j 2022 |b 30 |c 05 |h 108666 | ||